Since somatic mutations of the TGFβ pathway may promote or block tumourigenesis depending on the stage of the disease, this is important to bear in mind when assessing the benefits and risks of using TGFβ signalling inhibitors in cancer treatment (Khoshakhlagh et al., 2019). This evidence concerns the gene TGFB1 and cancer.